$96.24
1.72% yesterday
NYSE, Jan 21, 10:13 pm CET
ISIN
US58933Y1055
Symbol
MRK

Merck & Co. Stock price

$96.24
-3.13 3.15% 1M
-29.45 23.43% 6M
-3.24 3.26% YTD
-23.19 19.42% 1Y
+16.26 20.33% 3Y
+10.45 12.18% 5Y
+36.97 62.37% 10Y
NYSE, Closing price Tue, Jan 21 2025
-1.68 1.72%
ISIN
US58933Y1055
Symbol
MRK
Sector
Industry

Key metrics

Market capitalization $247.70b
Enterprise Value $271.26b
P/E (TTM) P/E ratio 20.51
EV/FCF (TTM) EV/FCF 18.28
EV/Sales (TTM) EV/Sales 4.31
P/S ratio (TTM) P/S ratio 3.94
P/B ratio (TTM) P/B ratio 5.57
Dividend yield 3.19%
Last dividend (FY24) $3.12
Revenue growth (TTM) Revenue growth 8.17%
Revenue (TTM) Revenue $62.89b
EBIT (operating result TTM) EBIT $14.47b
Free Cash Flow (TTM) Free Cash Flow $14.84b
Cash position $14.64b
EPS (TTM) EPS $4.77
P/E forward 13.73
P/S forward 3.87
EV/Sales forward 4.24
Short interest 1.22%
Show more

Create a Free Account to create an Merck & Co. alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Merck & Co. Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Merck & Co. forecast:

18x Buy
67%
9x Hold
33%

Analyst Opinions

27 Analysts have issued a Merck & Co. forecast:

Buy
67%
Hold
33%

Financial data from Merck & Co.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
62,893 62,893
8% 8%
100%
- Direct Costs 16,965 16,965
2% 2%
27%
45,928 45,928
12% 12%
73%
- Selling and Administrative Expenses 6,463 6,463
0% 0%
10%
- Research and Development Expense 20,800 20,800
8% 8%
33%
18,665 18,665
58% 58%
30%
- Depreciation and Amortization 4,198 4,198
10% 10%
7%
EBIT (Operating Income) EBIT 14,467 14,467
80% 80%
23%
Net Profit 12,148 12,148
164% 164%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Merck & Co. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Merck & Co. Stock News

Neutral
The Motley Fool
about 14 hours ago
2024 was an excellent year for the major stock market indexes. But the Dow Jones Industrial Average (^DJI 0.78%) had just a 12.9% return, compared to 23.3% for the S&P 500 (^GSPC 1.00%) and 28.6% for the Nasdaq Composite.
Positive
Seeking Alpha
one day ago
Merck's current discounted valuation, and robust pipeline advancements, which tripled over the past 3+ years, present a compelling long-term investment opportunity. Its strong business performance with 7% YoY revenue growth, driven by Keytruda and GARDASIL expansions, supports Merck's solid financial health. Merck's 3.3% dividend yield, low net debt-to-EBITDA ratio, and promising late-stage ass...
Positive
Seeking Alpha
one day ago
A list of high-quality dividend-growth stocks trading near 52-week lows is evaluated based on historical and future fair values. Merck's robust Phase 3 pipeline, strong financials, and sustainable dividend make it a compelling investment despite risks like Medicare negotiations and patent expirations. Merck also appears to have good potential for future growth.
More Merck & Co. News

Company Profile

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Head office United States
CEO Robert Davis
Employees 72,000
Founded 1891
Website www.merck.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today